Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/jpet.110.170191PMID 20543097PMCID PMC2939673
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anthracyclines in the Treatment of Cancer

  2012cited by this paper
• Protective effects of tadalafil on experimental spinal cord injury in rats.

  2010cited by this paper
• Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide

  2009cited by this paper
• cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium

  2009cited by this paper
• Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice

  2008cited by this paper
• Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β*

  2008cited by this paper
• Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H2O2 generation by rat heart mitochondria

  2008cited by this paper
• Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

  2007cited by this paper
• Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy

  2007cited by this paper
• The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

  2007cited by this paper
• Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.

  2006cited by this paper
• Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?

  2006cited by this paper
• Tadalafil pharmacokinetics in healthy subjects.

  2006cited by this paper
• Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult Cardiomyocyte*

  2006cited by this paper
• Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte Viability

  2006cited by this paper
• Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity

  2005cited by this paper
• Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

  2005cited by this paper
• Signal transduction by erythrocytes on specific binding of doxorubicin immobilized on nanodispersed magnetite

  2005cited by this paper
• Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity.

  2004cited by this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004cited by this paper
• Sildenafil-induced cardioprotection in rabbits.

  2003cited by this paper
• Cardiovascular effects of sildenafil in experimental ischemia–reperfusion (reply to “Sildenafil-induced cardioprotection in rabbits, by Kukreja, R.C., Ockaili, R., Salloum, F., Xi, L.”)

  2003cited by this paper
• Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse Heart

  2003cited by this paper
• Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.

  2002cited by this paper
• Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia

  2002cited by this paper
• Phosphodiesterase 5 inhibitors: current status and potential applications

  2002cited by this paper
• Protective effect of arabic gum against cardiotoxicity induced by doxorubicin in mice: A possible mechanism of protection

  2002cited by this paper
• Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction

  2002cited by this paper
• Adriamycin-induced heart failure: mechanisms and modulation

  2000cited by this paper
• Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.

  2000cited by this paper
• Mechanism of Doxorubicin-Induced Inhibition of Sarcoplasmic Reticulum Ca2+-ATPase Gene Transcription

  2000cited by this paper
• Doxorubicin-Induced Cardiomyopathy

  2000cited by this paper
• Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription.

  1999cited by this paper
• Doxorubicin-induced cardiomyopathy.

  1998cited by this paper
• Anthracyclines in the treatment of cancer. An overview.

  1997cited by this paper
• Primary Prevention of Coronary Heart Disease

  1997cited by this paper
• Suppression of Doxorubicin Cardiotoxicity by Overexpression of Catalase in the Heart of Transgenic Mice (*)

  1996cited by this paper
• The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice.

  1996cited by this paper
• Granulocyte Colony-Stimulating Factor in Amniotic Fluid

  1995cited by this paper
• A new insight into adriamycin-induced cardiotoxicity.

  1990cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper
• Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.

  1986cited by this paper
• Effects of first‐dose doxorubicin on cardiac rhythm as evaluated by continuous 24‐hour monitoring

  1985cited by this paper
• Anthracycline cardiomyopathy monitored by morphologic changes.

  1978cited by this paper
• Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

  1977cited by this paper
• A clinicopathologic analysis of adriamycin cardiotoxicity

  1973cited by this paper

• Cinsel aktivite ve fosfodiesteraz Tip 5 inhibitörleri: Kardiyovasküler risk faktörü mü?

  2025cites this paper
• Potential beneficial impacts of tadalafil on cardiovascular diseases

  2025cites this paper
• Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies

  2025cites this paper
• Vericiguat Attenuates Doxorubicin-Induced Cardiotoxicity through the PRKG1/PINK1/STING Axis.

  2024cites this paper
• PDE-5-Inhibited BMSCs Alleviate High Glucose-Induced Myocardial Fibrosis and Cardiomyocyte Apoptosis by Activating the cGMP/PKG Pathway.

  2023cites this paper
• Androgen deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: Effect of sildenafil.

  2023cites this paper
• Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review

  2023cites this paper
• Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

  2023cites this paper
• Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

  2022cites this paper
• Phosphodiesterase 5a Signalling in Skeletal Muscle Pathophysiology

  2022cites this paper
• Cardiotoxicity linked to anticancer agents and cardioprotective strategy

  2022cites this paper
• Potential cardiotoxicity induced by Euodiae Fructus: In vivo and in vitro experiments and untargeted metabolomics research

  2022cites this paper
• The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

  2022cites this paper
• Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity

  2022cites this paper
• Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial

  2022cites this paper
• TRPC6 N338S is a gain-of-function mutant identified in patient with doxorubicin-induced cardiotoxicity.

  2022cites this paper
• Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile

  2021cites this paper
• Tadalafil in Increasing Doses: The Influence on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts

  2021cites this paper
• CARDIOTOXIC EFFECT OF CHEMOTHERAPEUTIC AGENTS

  2021cites this paper
• Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity

  2020cites this paper
• Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway

  2020cites this paper
• GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes

  2020cites this paper
• Myocardial Phosphodiesterases and their Role in cGMP Regulation.

  2020cites this paper
• Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats.

  2020cites this paper
• Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.

  2020cites this paper
• Targets of cGMP/cGKI in cardiac myocytes.

  2020cites this paper
• Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure

  2020cites this paper
• Phosphodiesterase inhibitors say NO to Alzheimer's disease.

  2019cites this paper
• Kiwifruit extract attenuates tadalafil induced retinal injury in adult male albino rats: a histological and immunohistochemical study

  2019cites this paper
• Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

  2019cites this paper
• The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It?

  2019cites this paper
• The environmental pollutant BDE-209 regulates NO/cGMP signaling through activation of NMDA receptors in neurons

  2018cites this paper
• Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression

  2018cites this paper
• Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

  2018cites this paper
• Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

  2018cites this paper
• Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

  2018cites this paper
• Antiproliferative activity of the combination of doxorubicin/quercetin on MCF7 breast cancer cell line: A combined study using colorimetric assay and synchrotron infrared microspectroscopy

  2018cites this paper
• Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention

  2018cites this paper
• Phosphodiesterase type 5 and cancers: progress and challenges

  2017cites this paper
• Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.

  2017cites this paper
• Folic acid reduces doxorubicin‐induced cardiomyopathy by modulating endothelial nitric oxide synthase

  2017cites this paper
• Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice

  2017cites this paper
• Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.

  2017cites this paper
• Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors

  2017cites this paper
• Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation*

  2016cites this paper
• The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities

  2016cites this paper
• Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.

  2016cites this paper
• Chemopreventive Effect of Tadalafil in Cisplatin-Induced Nephrotoxicity in Rats.

  2016cites this paper
• Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury

  2016cites this paper
• Musclees and Cyclic GMP Regulation in Heart

  2016cites this paper
• Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.

  2016cites this paper
• Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies

  2016cites this paper
• Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin

  2016cites this paper
• Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95

  2015cites this paper
• Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats.

  2015cites this paper
• PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

  2015cites this paper
• Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.

  2015cites this paper
• Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity.

  2014cites this paper
• Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.

  2014cites this paper
• Sildenafil Exposure and Hemodynamic Effect After Fontan Surgery

  2014cites this paper
• Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.

  2014cites this paper
• PDE-5 Inhibitors in Protection of Diabetic Heart

  2014cites this paper
• Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.

  2013cites this paper
• Complications of chemotherapy, a basic science update.

  2013cites this paper
• Investigation into the cardiotoxic effects of doxorubicin and strategies for cardioprotection

  2013cites this paper
• Sildenafil and cardioprotection.

  2013cites this paper
• Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line.

  2013cites this paper
• Efficacy of tadalafil in chronic hypobaric hypoxia–induced pulmonary hypertension: possible mechanisms

  2013cites this paper
• Phosphodiesterase-5 Inhibitors in Cardioprotection

  2013cites this paper
• Effects of Tadalafil on Hemorrhagic Cystitis and Testicular Dysfunction Induced by Cyclophosphamide in Rats

  2013cites this paper
• Attenuation of Doxorubicin-Induced Cardiotoxicity by mdivi-1: A Mitochondrial Division/Mitophagy Inhibitor

  2013cites this paper
• Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice.

  2013cites this paper
• Efeitos da inibição da fosfodiesterase-5 sobre a disfunção diastólica do ventrículo esquerdo em pacientes com hipertensão arterial resistente

  2013cites this paper
• Pulmonary Venous Hypertension- An On Going Quest for Treatment: Is PDE5 Inhibition the Right Solution?

  2012cites this paper
• A Review on the Potential Benefits of Phosphodiesterase Inhibitors in Various Models of Toxicities in Animals

  2012cites this paper
• NOVEL STRATEGIES TO IMPROVE METABOLIC PARAMETERS AND PRECONDITION DIABETIC HEARTS AGAINST ISCHEMIA/REPERFUSION INJURY

  2012cites this paper
• Cardiac uses of phosphodiesterase-5 inhibitors.

  2012cites this paper
• Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

  2012cites this paper
• Preconditioning by Phosphodiesterase‐5 Inhibition Improves Therapeutic Efficacy of Adipose‐Derived Stem Cells Following Myocardial Infarction in Mice

  2012cites this paper
• Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats

  2012cites this paper
• PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update.

  2012cites this paper
• Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts

  2012cites this paper
• Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

  2012cites this paper
• Phosphodiesterases and cyclic GMP regulation in heart muscle.

  2012cites this paper
• Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/− mice

  2012cites this paper
• Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice

  2012cites this paper
• Heart failure: a PKGarious balancing act.

  2012cites this paper
• Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine

  2011cites this paper
• Mechanisms and management of doxorubicin cardiotoxicity

  2011cites this paper
• Phosphodiesterase-5 Inhibitors in Protection Against Doxorubicin-Induced Cardiomyopathy

  2011cites this paper
• Phosphodiesterases and cardiac cGMP: evolving roles and controversies.

  2011cites this paper
• Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect

  2011cites this paper
• The Role of PDE-5 Inhibitors in Prostate Cancer

  2011cites this paper
• Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010)

  2011cites this paper
• PHOSPHODIESTERASE-5 INHIBITION: A NOVEL STRATEGY TO IMPROVE STEM CELL THERAPY IN THE HEART

  2011cites this paper
• Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity

  2011cites this paper
• Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

  2011cites this paper
• Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis.

  2011cites this paper